Regeneron Pharmaceuticals PT Raised to $422.00 at Roth Capital (REGN)
Analysts at Roth Capital lifted their target price on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from $399.00 to $422.00 in a research report issued to clients and investors on Wednesday. Roth Capital’s price target points to a potential upside of 17.39% from the company’s current price.
In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 2,000 shares of the stock on the open market in a transaction dated Wednesday, August 27th. The shares were sold at an average price of $350.31, for a total transaction of $700,620.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 0.82% on Wednesday, hitting $362.46. 250,466 shares of the company’s stock traded hands. Regeneron Pharmaceuticals has a 1-year low of $255.00 and a 1-year high of $369.31. The stock has a 50-day moving average of $329.7 and a 200-day moving average of $312.8. The company has a market cap of $36.387 billion and a price-to-earnings ratio of 102.31.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings data on Tuesday, August 5th. The company reported $2.47 earnings per share for the quarter, beating the analysts’ consensus estimate of $2.30 by $0.17. The company had revenue of $666.00 million for the quarter, compared to the consensus estimate of $647.99 million. During the same quarter last year, the company posted $1.73 earnings per share. Regeneron Pharmaceuticals’s revenue was up 45.4% compared to the same quarter last year. Analysts expect that Regeneron Pharmaceuticals will post $10.15 EPS for the current fiscal year.
A number of other firms have also recently commented on REGN. Analysts at Brean Capital raised their price target on shares of Regeneron Pharmaceuticals from $380.00 to $390.00 in a research note on Tuesday. They now have a “buy” rating on the stock. Separately, analysts at Morgan Stanley reiterated an “equal weight” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday. They now have a $310.00 price target on the stock. Finally, analysts at Credit Suisse raised their price target on shares of Regeneron Pharmaceuticals from $340.00 to $400.00 in a research note on Tuesday. They now have an “outperform” rating on the stock. One research analyst has rated the stock with a sell rating, six have issued a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $357.50.
Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.